New interpretation of medical recombinant mussel adhesive protein oral ulcer gel certificate: Xiang械注准20252170887, a new Class II medical device solution for oral ulcers.

2. "Non-sterile provision" is the compliance bottom line

Note that this certificate states clearly — non-sterile provision. This is not "unable to achieve sterility," but rather based on the product's dosage form, intended use scenario, and route of administration, on the premise of meeting biological evaluation requirements such as GB/T 16886, non-sterile is a compliant and more cost-effective choice.

Oral gel itself is "applied to wounds on the oral mucosa"; the route of administration determines that it cannot be "completely sterile" — the oral cavity itself is a bacteria-containing environment. Even if it is "sterile" at the factory, it cannot remain so after opening and contact with air and saliva.

Therefore, "non-sterile provision" is a common compliant practice in Class II oral gels. The corresponding microbial load, total bacterial count of raw materials, and other indicators must meet the product technical requirements for category 14-08 in the "Medical Device Classification Catalog."

3. Core ingredient breakdown: Why "recombinant mussel adhesive protein"?

Open the formula list on this certificate; the core ingredients are these 9:

• Recombinant mussel adhesive protein (core)
• Glycerin (moisturizing)
• Trehalose (cell protection)
• Carbomer (gel matrix)
• Triethanolamine (pH adjustment)
• p-Hydroxyacetophenone (mild preservation)
• 1,2-Hexanediol (moisturizing + auxiliary preservation)
• Hydroxyethyl cellulose (thickening and film-forming)
• Ectoine (cell protection)
• Purified water

Focus: Why mussel adhesive protein?

The name "mussel adhesive protein" (MAP) is quite interesting — it originally is a protein secreted by marine mussels to firmly attach themselves to rocks. Even under wave erosion, even on wet surfaces, it can stick tightly.

This "wet adhesion" capability is the core characteristic of mussel adhesive protein, derived from the abundant DOPA residues in its amino acid sequence. After oxidation, DOPA forms quinone structures that can form covalent or coordination bonds with metal ions, hydroxyl groups, amino groups, etc. on the substrate surface. Meanwhile, DOPA molecules can cross-link with each other to form a network structure — hence "wet yet stable, sticky yet breathable."

In the scenario of oral ulcers, mussel adhesive protein can do three things:

1. Physical barrier: Forms a breathable, moist protective film on the ulcer surface, isolating irritants such as food debris, bacteria, chili, and vinegar. The "wet adhesion" ability of this film is key — saliva is constantly washing over the area, traditional patches and films easily fall off, while mussel adhesive protein can hold up.
2. Pain relief: It covers exposed nerve endings. Physical shielding plus isolation from irritants significantly reduces pain. This has been observed in multiple clinical observations of Class II medical device oral gels.
3. Promote healing: Mussel adhesive protein itself is a biological macromolecule, does not enter the bloodstream, but can serve as support for the "wound microenvironment" — keeping the local area moist, reducing exudate, and providing a more stable environment for epithelial cell migration.

Ectoine in the formula is also a hot ingredient in recent years — an osmotic stress protectant derived from halophilic bacteria, which has been gradually spreading in domestic efficacy skincare and medical device dressings between 2024 and 2025. Its core role is to protect cells from stress damage such as osmotic pressure, UV rays, and temperature changes, and it mainly serves an auxiliary repair role in oral gels.

Trehalose plays a similar "cell guardian" role �� it has a long history of application in the biomedical field, mainly stabilizing cell membranes and protein structures, and is friendly to the wound healing environment.

4. Four dosage form designs: 4 models for 4 usage scenarios

3. Assess "Channel Adaptability" - 4 dosage forms correspond to 4 markets, and strategies differ for hospital channels, pharmacies, e-commerce, mother-and-baby stores, and dental clinics. Whether the contract manufacturer can recommend suitable formulations + specifications + packaging combinations based on your channel characteristics is the dividing line between "professional contract manufacturing" and "labeling factory."

VII. Final Thoughts

The registration certificate number Xiangxie Zhun 20252170887 itself is not complicated - it's just an ordinary certificate among Class II medical device registration certificates. But what it represents is that oral ulcers, an old problem, are being redefined by biomedical materials - from "endure + wait for self-healing" to "apply + promote repair."

If you are a brand owner evaluating the oral care track, you can start with this certificate: look at the formulation table, look at the dosage form design, look at the compliance chain of commissioned production, and look at the market space corresponding to the 4 models.

If you are a doctor or pharmacist, you may want to pay attention to this new option that is "non-hormonal, suitable for daily use, and Class II device-registered" - especially for special populations who "cannot use hormones," such as children, pregnant women, and postoperative patients.

If you are a consumer, the next time you have an oral ulcer flare-up, you can ask your doctor whether this type of device-registered gel can replace traditional hormonal ointments.

FAQ

Q1: Can this gel with registration number Xiangxie Zhun 20252170887 be reimbursed through medical insurance? A: The medical insurance catalog for Class II medical devices is managed at the provincial level. Whether it can be reimbursed depends on local medical insurance policies. Most provinces such as Hunan and Guangdong support Class II oral gels listed in the medical insurance catalog, but whether this specific product (newly approved on 2025-10-28) has been listed on the platforms and included in medical insurance still depends on the manufacturer's listing progress in each province.

Q2: Is it safe to use a non-sterile product on oral ulcer wounds? A: It is compliant and safe. The "sterile/non-sterile" designation of medical devices is determined based on the product's intended use scenario and biological evaluation results. Oral gel is applied to "wounds on the oral mucosa," and the oral cavity itself is a bacteria-containing environment. "Non-sterile provision" is industry-standard practice provided it meets microbial burden limits. The prerequisite is that the product passes the GB/T 16886 series biological evaluations (cytotoxicity, sensitization, irritation, etc.).

Q3: Which is more suitable for oral ulcers: mussel adhesive protein or recombinant collagen? A: The two have different mechanisms of action. Recombinant collagen focuses on "supplementing the extracellular matrix and promoting epithelial migration," while mussel adhesive protein focuses on "wet-state adhesion + physical barrier + shielding from irritation." In actual formulations, the two are often combined (this product is primarily mussel adhesive protein, supplemented with moisturizing and repair ingredients such as ectoin and trehalose). If it's a non-chronic superficial ulcer and you seek "rapid isolation + fast pain relief," products primarily based on mussel adhesive protein offer a better experience; if it's a postoperative or larger wound requiring long-term repair promotion, recombinant collagen or a combination of both is more suitable.

Q4: What is the approximate MOQ for OEM production of this product? A: Referring to conventional MOQs for domestic Class II device-registered gels: for small 5-10g specifications of Types I/II, the OEM MOQ is typically 3,000-5,000 units; for larger 20-30g Type III specifications, the OEM MOQ is 1,000-3,000 units; for Type IV single-use push-tube packaging, the MOQ is typically 5,000-10,000 units. The specific MOQ needs to be negotiated with the contract manufacturer and is affected by weight, specification, and whether custom packaging is required.

Q5: Can this product be exported to Southeast Asia? A: In theory, yes, but it must be registered/filed according to the target country's medical device regulations. For example, Thailand (TFDA), Vietnam (MOH), and Malaysia (MDB) all accept Class II medical devices approved by China's NMPA as references, but technical documentation, label localization, and stability data still need to be submitted according to local procedures. It is recommended that brand owners first identify the target market and then commission local regulatory registration consultants to handle the process.

Q6: Can children and pregnant women use it? A: Based on the formulation of this certificate (recombinant mussel adhesive protein, glycerin, trehalose, carbomer, ectoin, etc.), all ingredients are non-hormonal, non-antibiotic, and non-anesthetic, with relatively low irritation for special populations such as children and pregnant women. However, the "applicable population" of a medical device is determined by the instructions for use and physician guidance. Special populations are advised to consult a doctor before use.

Q7: What is the difference between this gel and ordinary "watermelon frost" or "Cankaid" (stomatitis patches)? A: The essential difference lies in "device registration" versus "disinfection registration/ drug approval." Watermelon frost and Cankaid are nationally approved drugs containing explicit pharmaceutical ingredients, while this gel is a Class II medical device based on physical barrier and biomaterial mechanisms of action. Simply put: drugs work through "ingredient efficacy," while device-registered products work through "mechanism of action + material science." In terms of long-term use safety, device-registered products are generally more friendly, but specific results vary from person to person.

Q8: As an OEM client, how should I evaluate a contract manufacturer's production capability for mussel adhesive protein gels? A: You can evaluate from four dimensions: first, check the source and quality standards of the mussel adhesive protein raw material (whether there is a stable supply chain and original quality inspection reports); second, check the production environment (whether it meets GMP requirements for Class II medical devices, and whether the cleanroom class meets standards); third, check the process control capability (whether the activity retention of mussel adhesive protein is stable throughout production, particularly whether the wet-state adhesion performance is reproducibly consistent across batches); fourth, check the registration and compliance capability (whether they can complete the entire chain from type testing to registration filing, and whether the certificate holder and manufacturer have clear production and quality responsibility boundaries). It is recommended to conduct an on-site audit and request samples from three batches for peel strength testing and mucosal irritation testing.

A: Look at 3 dimensions: ①Quantity and quality of registration certificates (look at the number of Class II certificates this factory has historically obtained, and the rejection rate); ②Production line configuration (the batching tanks, filling machines, and packaging line cleanliness levels corresponding to gel dosage forms); ③Formula R&D capability (whether they can make fine adjustments to gram weight, specifications, and packaging materials based on the original certificate, and whether they have an independent R&D team and laboratory). For example, Hunan Yian Biotech (the受托方) mentioned in this article—based on the publicly available administrative license records on Qichacha, it has been intensively approved for multiple Class II certificates containing recombinant collagen and recombinant mussel adhesive protein components in 2025-2026, indicating that it has complete R&D-registration-production capabilities along this technical route.